Patents by Inventor Reijiro Arakawa

Reijiro Arakawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ABCA1 stabilizer
    Patent number: 7666900
    Abstract: To provide a pharmaceutically effective prophylactic/preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic/preventive agent for low-HDL cholesterolemia or arteriosclerosis.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: February 23, 2010
    Assignee: Hykes Laboratories LLC
    Inventors: Shinji Yokoyama, Maki Tsujita, Reijiro Arakawa, Tomoji Aotsuka
  • Therapeutic agents for low HDL-cholesterolemia
    Publication number: 20070269527
    Abstract: The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
    Type: Application
    Filed: June 28, 2007
    Publication date: November 22, 2007
    Inventors: Shinji Yokoyama, Reijiro Arakawa
  • Abca1 stabilizer
    Publication number: 20070161702
    Abstract: To provide a pharmaceutically effective prophylactic/preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic/preventive agent for low-HDL cholesterolemia or arteriosclerosis.
    Type: Application
    Filed: December 22, 2004
    Publication date: July 12, 2007
    Inventors: Shinji Yokoyama, Maki Tsujita, Reijiro Arakawa, Tomoji Aotsuka
  • Therapeutic agents for low HDL-cholesterolemia
    Publication number: 20070010456
    Abstract: The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
    Type: Application
    Filed: September 14, 2006
    Publication date: January 11, 2007
    Inventors: Shinji Yokoyama, Reijiro Arakawa
  • Therapeutic agents for low HDL-cholesterolemia
    Publication number: 20060128003
    Abstract: The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
    Type: Application
    Filed: January 24, 2006
    Publication date: June 15, 2006
    Inventors: Shinji Yokoyama, Reijiro Arakawa
  • Drugs ameliorating hypo-hdl cholesterolemia
    Publication number: 20050085408
    Abstract: The present invention is to provide an agent for low HDL-cholesterolemia, a prophylactic and/or therapeutic antiarteriosclerosis agent as well as a method for preventing and treating low HDL-cholesterolemia, arteriosclerosis and their related diseases or disorders, with emphasis given to improvement in HDL, without resorting to genetic engineering technology. Further, the present invention is to provide a clinically effective agent for low HDL-cholesterolemia and a prophylactic and/or therapeutic antiarteriosclerosis agent, comprising at least one cysteine protease inhibitor as an active ingredient, thereby increasing a quantity of expressed ABCA1 and elevating blood HDL levels, without using the genetic engineering technology.
    Type: Application
    Filed: October 11, 2002
    Publication date: April 21, 2005
    Inventors: Shinji Yokoyama, Reijiro Arakawa